Product logins

Find logins to all Clarivate products below.


Biosimilars Advisory Service : Global Biosimilars Markets – Regulations, Pipelines, and Major Players | G7 | 2015

Latest update: Global Biosimilars Pipeline updated on 31 July 2015

The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 75% of branded biologics sales, the rest-of-world segment includes many markets where treatment rates with branded biologics are currently low due to their high costs. Therefore, opportunity exists for biosimilars to expand the market and provide better access to biologic therapy. Regulators in more than 20 of the growth markets have adopted biosimilars guidelines and are eager to establish their own biosimilars industries. A wide range of companies are embarking on biosimilars development within their domestic markets and overseas. Understanding who the key competitors are in each region is critical to both biosimilar developers and branded biologic companies.

Related Market Assessment Reports

Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Biosimilars – Access & Reimbursement – Access & Reimbursement Global Landscape
The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 719 currently available and novel biosimilar products, detailing…
Report
Biosimilars – Forecast – Ophthalmology
In 2023, sales of branded biologics in ophthalmology exceeded $9.8 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period…
Report
Biosimilars – Forecast – Respiratory
In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033…